Maven Securities LTD Invests $774,000 in Cogent Biosciences, Inc. $COGT

Maven Securities LTD acquired a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 20,000 shares of the technology company’s stock, valued at approximately $774,000.

Several other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC grew its position in Cogent Biosciences by 482.6% in the 1st quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company’s stock worth $963,000 after purchasing an additional 133,174 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Cogent Biosciences by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock worth $377,000 after buying an additional 3,693 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Cogent Biosciences by 14.3% during the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock worth $5,924,000 after buying an additional 124,069 shares during the period. Jane Street Group LLC grew its holdings in Cogent Biosciences by 66.2% in the 1st quarter. Jane Street Group LLC now owns 123,822 shares of the technology company’s stock worth $742,000 after buying an additional 49,338 shares in the last quarter. Finally, Strs Ohio bought a new position in Cogent Biosciences in the 1st quarter worth approximately $36,000.

Cogent Biosciences Price Performance

NASDAQ COGT opened at $35.28 on Wednesday. Cogent Biosciences, Inc. has a 12 month low of $11.60 and a 12 month high of $43.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 13.57 and a quick ratio of 13.57. The firm has a market capitalization of $6.12 billion, a PE ratio of -16.33 and a beta of 0.31. The company’s 50 day simple moving average is $38.35 and its 200 day simple moving average is $36.48.

Cogent Biosciences (NASDAQ:COGT) last announced its earnings results on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. As a group, equities research analysts forecast that Cogent Biosciences, Inc. will post -2.25 EPS for the current fiscal year.

Analyst Ratings Changes

COGT has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Guggenheim boosted their price target on Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wedbush reissued an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a research note on Friday, May 29th. Wall Street Zen lowered Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Piper Sandler lifted their price objective on shares of Cogent Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.56.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.